To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully understanding the various factors affecting ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...